Case study - Keranova
KERANOVA
KERANOVA is a fast-growing start-up developing a breakthrough ophthalmologic technology. They design and develop robotic surgical equipment for various diseases of the anterior segment of the eye. The company is using a unique patented technology that represents a major advance in ophthalmologic surgical procedures.
KERANOVA’s first device addressed cataracts and could tackle refractory problems, such as myopia and astigmatism. This innovative approach protected by 11 patent families provides a rethinking of surgical procedures and reduces manual procedures in favour of automation and precision. The device has been successfully validated in a first in human study.
Our investment was motivated by:
- A company with a pre-clinically proven disruptive technology, a strong IP portfolio and an “A” team
- A sector where stakeholders are in search for a technological leap
Since its initial investment in 2016, MxEP has provided support on several fronts such as:
- Leverage our network to expand the team and build an international SAB
- Leverage synergies with another portfolio company (femtolaser manufacturer)
- Support the management on building regulatory and clinical strategy for the US market
- Discuss several options for Series B fund raising
- Prepare a “build to buy” deal with management
MxEP was instrumental in helping us refine our business model and roadmaps […] and an invaluable partner in the financing process but also in the day-to-day development of our business by opening up their network of experts to us and by supporting us through all the key stages with a cooperative approach.